Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

595 trials

NCT06536413
Recruiting
ATRA and Carfilzomib in Plasma Cell Myeloma Patients
Phase 1/2 · United States · 1 site
Registry update: 3 Apr 2026
NCT06485076
Recruiting
Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma
Not applicable · Canada · 1 site
Registry update: 3 Dec 2025
NCT06207799
Recruiting
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma
Phase 2 · United States · 1 site
Registry update: 10 Aug 2026
NCT06515249
Recruiting
Integrative Therapies in Multiple Myeloma
Not applicable · Israel · 1 site
Registry update: 30 Sept 2026
NCT06145581
Recruiting
Remote Monitoring With Health-Coaching to Improve Quality of Life in Older Patients With Multiple Myeloma
Not applicable · United States · 1 site
Registry update: 13 Apr 2026
NCT06430736
Recruiting
PRONTO Trial (PRophylactic Versus ON-demand Use of TOcilizumab)
Phase 2 · Switzerland · 1 site
Registry update: 8 Jul 2024
NCT06515262
Recruiting
Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM
Not applicable · China · 1 site
Registry update: 23 Jul 2024
NCT06296368
Recruiting
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
Not applicable · United States · 1 site
Registry update: 14 Aug 2026
NCT06115135
Recruiting
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Phase 2 · United States · 2 sites
Registry update: 16 Jan 2025
NCT06505369
Recruiting
Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients
Phase 2 · Denmark, Estonia, Norway · 7 sites
Registry update: 17 Jul 2024
NCT06508983
Recruiting
A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
Phase 3 · China · 12 sites
Registry update: 10 Jul 2026
NCT06574568
Recruiting
A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
Phase 1 · China · 12 sites
Registry update: 5 Feb 2026
NCT06409702
Recruiting
Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
Phase 4 · China · 1 site
Registry update: 12 Jun 2025
NCT06224309
Recruiting
Preliminary Assessment of [18F]BL40 in PET/CT Scans
Not applicable · Canada · 1 site
Registry update: 1 Oct 2026
NCT06407947
Recruiting
Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma
Early phase 1 · China · 1 site
Registry update: 12 Jun 2024
NCT05922501
Recruiting
Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
Phase 2 · United States · 2 sites
Registry update: 14 Jan 2026
NCT06375044
Recruiting
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Phase 1 · China, United States · 16 sites
Registry update: 28 Aug 2026
NCT06187441
Recruiting
FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)
Phase 3 · Netherlands · 64 sites
Registry update: 19 Aug 2024
NCT05530096
Recruiting
Telo Genomics Technology to Detect & Profile Multiple Myeloma MRD
Not applicable · Canada · 1 site
Registry update: 3 Apr 2025
NCT06539832
Recruiting
Intestinal Flora and Immunity in Monoclonal Gammopathy Patients
Not applicable · China · 1 site
Registry update: 19 Sept 2024

Ordered by registry start date. Freshness and sponsorship never change the order.